Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

XORTX Therapeutics Prices $12m Public Offering 

Published 14/10/2021, 07:08 am
Updated 14/10/2021, 07:08 am
© Reuters.

© Reuters.

By Sam Boughedda

Investing.com — XORTX Therapeutics (NASDAQ: XRTX) announced the pricing of its public offering on Wednesday, with A.G.P./Alliance Global acting as the sole book-running manager. 

The pharmaceutical company develops therapies to treat progressive kidney disease. It priced 2.9 million units, with each unit comprising one common share of no par value and one warrant to purchase one common share at a public offering price of $4.13 per unit. 

The company wants to raise approximately $12 million.

The warrants have an initial exercise price of $4.77 per share and are immediately exercisable, with a term of approximately five years.

Additionally, XORTX has given the underwriters a 45-day option to purchase up to an additional 435,900 shares, or warrants to purchase up to a further 435,900 shares at the offering price.

XORTX has received conditional approval to list its common shares on the Nasdaq under the ticker symbol “XRTX” and began trading today. The offering is expected to close on or around October 15.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.